4793 Encainide All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. 66778-36-7 C22H28N2O2 White powder. Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Route of Elimination: A radiolabeled dose of encainide is excreted in approximately equal amounts in the urine and feces. Half Life: 1-2 hours No indication of carcinogenicity to humans (not listed by IARC). Encainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. 2014-09-11T05:14:08Z 2014-12-24T20:26:56Z Encainide C06978 4788 DB01228 true COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C C22H28N2O2 InChI=1/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25) InChIKey=PJWPNDMDCLXCOM-UHFFFAOYNA-N 352.4699 352.21507815 Exogenous Solid 4 CHEMBL570071 <p><a href="http://www.drugsyn.org/Encainide.htm">DrugSyn.org</a></p>